04/17/2026
BREAKING: peptides are back.
For the past 2+ years, 12 therapeutic peptides sat on the FDA’s restricted “Category 2” list — pharmacies couldn’t compound them, clinicians couldn’t prescribe them, and demand quietly migrated to gray-market suppliers overseas.
The FDA just announced plans to remove them.
The peptides coming back: BPC-157, Semax, DSIP, KPV, TB-500, MOTs-C, GHK-Cu, Cathelicidin LL-37, Melanotan II, MK-677, Dihexa Acetate, Epitalon.
The 2023 restriction was never supported by documented patient harm. It just pushed demand into the exact black market it claimed to prevent.
This reversal does four things:
– Restores legitimate clinician access
– Ends the gray-market workaround
– Reopens safer, data-driven protocols
– Signals a broader rethink of peptide regulation
Starting in July, independent experts will evaluate each compound on its actual clinical evidence. More changes are likely coming.
At Protocol Health, we’re monitoring closely and advocating for safe, regulated access, physician-led protocols, and evidence-based peptide therapy — not the algorithm-chasing version you’re seeing everywhere else.
Comment “CONSULT” and we’ll DM you a link to book a consultation.